Guggenheim analyst Jason Cassorla raised the firm’s price target on Elevance Health (ELV) to $414 from $398 and keeps a Buy rating on the shares. Intra-quarter management commentary, a pre-quiet period catch-up with the company, and investor conversations point to “a solid setup for 2026 expectations,” the analyst says.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Trump ‘Great Healthcare Plan’ a ‘win’ for insurers, says TD Securities
- Mizuho sees upcoming Medicare Advantage 2027 rates as positive catalyst
- Cantor says ‘Great Healthcare Plan’ favorable outcome for insurers
- Wells says ‘Great Healthcare Plan’ lacks new onerous proposals